T
4.23
0.03 (0.71%)
| Penutupan Terdahulu | 4.20 |
| Buka | 4.26 |
| Jumlah Dagangan | 1,887,600 |
| Purata Dagangan (3B) | 2,344,974 |
| Modal Pasaran | 3,067,582,976 |
| Harga / Pendapatan (P/E TTM) | 211.50 |
| Harga / Jualan (P/S) | 2.42 |
| Harga / Buku (P/B) | 3.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Keuntungan | 3.16% |
| Margin Operasi (TTM) | 0.67% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 54.20% |
| Nisbah Semasa (MRQ) | 1.79 |
| Aliran Tunai Operasi (OCF TTM) | 116.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.79 M |
| Pulangan Atas Aset (ROA TTM) | 1.58% |
| Pulangan Atas Ekuiti (ROE TTM) | 4.91% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BIODLINK-B | - | - |
AISkor Stockmoo
-1.8
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.75 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BIODLINK-B | 3 B | - | 211.50 | 3.52 |
| GENSCRIPT BIO | 25 B | - | - | 0.720 |
| CARSGEN-B | 8 B | - | - | 6.98 |
| LEPU BIO-B | 8 B | - | - | 10.02 |
| OCUMENSION-B | 6 B | - | - | 1.32 |
| JACOBIO-B | 5 B | - | - | 5.53 |
|
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 41.99% |
| % Dimiliki oleh Institusi | 28.40% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |